Conservative management without alkylating agents of squamous cell anal cancer using cyclical 5-FU alone and x-ray therapy
Byfield, J.E.; Barone, R.M.; Sharp, T.R.; Frankel, S.S.
Cancer Treatment Reports 67(7-8): 709-712
1983
ISSN/ISBN: 0361-5960 PMID: 6871886 Document Number: 197203
We have treated 11 patients with squamous cell anal carcinoma using a regimen of repeated cycles of 120-hour infused 5-FU (25 mg/kg/24 hours) and x-rays. Total radiation doses were between 3000 (palliative) and 4750 (curative) rads. Unlike all other equivalent combined-modality studies, no alkylating agent or drug other than 5-FU was used. With follow-up between 1 and 4 years, there has been only one local recurrence (coincident with terminal disseminated disease in a stage III patient treated palliatively). All other patients have maintained local control. Inclusion of alkylating agents (eg, mitomycin) in this approach can be questioned if the patient is willing to accept somewhat greater acute but reversible toxic effects.